Notice: This company has been marked as potentially delisted and may not be actively trading. Vermillion (VRML) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends VRML vs. ACHV, VNRX, OCX, ICCC, ORKA, AWH, TRIB, VRAX, CDIO, and BMRAShould you be buying Vermillion stock or one of its competitors? The main competitors of Vermillion include Achieve Life Sciences (ACHV), VolitionRx (VNRX), OncoCyte (OCX), ImmuCell (ICCC), Oruka Therapeutics (ORKA), Aspira Women's Health (AWH), Trinity Biotech (TRIB), Virax Biolabs Group (VRAX), Cardio Diagnostics (CDIO), and Biomerica (BMRA). These companies are all part of the "medical" sector. Vermillion vs. Achieve Life Sciences VolitionRx OncoCyte ImmuCell Oruka Therapeutics Aspira Women's Health Trinity Biotech Virax Biolabs Group Cardio Diagnostics Biomerica Achieve Life Sciences (NASDAQ:ACHV) and Vermillion (NASDAQ:VRML) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk, valuation, dividends and media sentiment. Which has stronger earnings and valuation, ACHV or VRML? Vermillion has higher revenue and earnings than Achieve Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchieve Life SciencesN/AN/A-$29.82M-$1.13-3.81Vermillion$4.54M15.28-$15.24MN/AN/A Does the MarketBeat Community prefer ACHV or VRML? Achieve Life Sciences received 130 more outperform votes than Vermillion when rated by MarketBeat users. Likewise, 70.46% of users gave Achieve Life Sciences an outperform vote while only 66.67% of users gave Vermillion an outperform vote. CompanyUnderperformOutperformAchieve Life SciencesOutperform Votes33470.46% Underperform Votes14029.54% VermillionOutperform Votes20466.67% Underperform Votes10233.33% Which has more risk and volatility, ACHV or VRML? Achieve Life Sciences has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Vermillion has a beta of 3.47, indicating that its stock price is 247% more volatile than the S&P 500. Is ACHV or VRML more profitable? Achieve Life Sciences has a net margin of 0.00% compared to Vermillion's net margin of -307.31%. Achieve Life Sciences' return on equity of -108.30% beat Vermillion's return on equity.Company Net Margins Return on Equity Return on Assets Achieve Life SciencesN/A -108.30% -65.20% Vermillion -307.31%-155.25%-103.47% Do insiders and institutionals hold more shares of ACHV or VRML? 33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 18.1% of Vermillion shares are held by institutional investors. 2.0% of Achieve Life Sciences shares are held by insiders. Comparatively, 4.4% of Vermillion shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer ACHV or VRML? In the previous week, Achieve Life Sciences had 13 more articles in the media than Vermillion. MarketBeat recorded 13 mentions for Achieve Life Sciences and 0 mentions for Vermillion. Achieve Life Sciences' average media sentiment score of 0.25 beat Vermillion's score of 0.00 indicating that Achieve Life Sciences is being referred to more favorably in the media. Company Overall Sentiment Achieve Life Sciences Neutral Vermillion Neutral Do analysts rate ACHV or VRML? Achieve Life Sciences presently has a consensus target price of $14.80, suggesting a potential upside of 244.19%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Achieve Life Sciences is more favorable than Vermillion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achieve Life Sciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Vermillion 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAchieve Life Sciences beats Vermillion on 13 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! Get Vermillion News Delivered to You Automatically Sign up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRML vs. The Competition Export to ExcelMetricVermillionDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.38M$2.51B$4.99B$8.74BDividend YieldN/A0.76%5.18%4.07%P/E Ratio-4.194.93131.5217.49Price / Sales15.2830.271,209.1089.52Price / CashN/A16.3433.2732.46Price / Book7.922.974.684.67Net Income-$15.24M$29.98M$117.80M$224.87M Vermillion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRMLVermillionN/A$0.71-4.0%N/A-77.2%$69.38M$4.54M-4.1943ACHVAchieve Life Sciences1.5523 of 5 stars$4.43+6.5%N/A-18.1%$152.35MN/A-3.9220VNRXVolitionRx2.2421 of 5 stars$0.65-1.5%N/A-7.7%$60.60M$770,000.00-1.8280Analyst ForecastGap UpOCXOncoCyte1.5327 of 5 stars$2.68+1.9%N/A-37.7%$45.10M$1.50M0.00120Analyst ForecastICCCImmuCell0.6076 of 5 stars$3.65+3.1%N/A-24.4%$32.52M$17.47M-7.3075News CoverageGap DownORKAOruka Therapeutics3.4575 of 5 stars$21.60+2.2%N/AN/A$26.14MN/A-3.45N/AAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeAWHAspira Women's Health1.5967 of 5 stars$0.74-0.1%N/A-78.1%$11.88M$9.15M-0.51110Analyst ForecastGap UpTRIBTrinity Biotech1.8892 of 5 stars$1.30-0.3%N/A-31.0%$9.87M$56.83M-0.57480Gap DownVRAXVirax Biolabs Group0.423 of 5 stars$1.91+1.5%N/A-27.4%$6.16M$160,000.000.005CDIOCardio Diagnostics2.176 of 5 stars$0.26-3.8%N/A-73.7%$6.13M$20,000.000.007Gap DownBMRABiomerica0.3493 of 5 stars$0.33-1.6%N/A-65.2%$5.54M$5.41M-0.8960Negative NewsGap Down Related Companies and Tools Related Companies Achieve Life Sciences Competitors VolitionRx Competitors OncoCyte Competitors ImmuCell Competitors Oruka Therapeutics Competitors Aspira Women's Health Competitors Trinity Biotech Competitors Virax Biolabs Group Competitors Cardio Diagnostics Competitors Biomerica Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRML) was last updated on 11/20/2024 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredAmazon's $150B Data Center Bet—What It Means for Uranium InvestorsAmazon is placing a massive bet on nuclear energy to power its $150 billion data center expansion. With dem...The Bull Report | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vermillion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vermillion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
